These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1524221)

  • 1. Drug release profiles of ophthalmic formulations. 1. Instrumentation.
    Stevens LE; Missel PJ; Lang JC
    Anal Chem; 1992 Apr; 64(7):715-23. PubMed ID: 1524221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limits on optimizing ocular drug delivery.
    Keister JC; Cooper ER; Missel PJ; Lang JC; Hager DF
    J Pharm Sci; 1991 Jan; 80(1):50-3. PubMed ID: 2013850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 2: Precorneal retention and in vivo pharmacodynamic study.
    Rupenthal ID; Green CR; Alany RG
    Int J Pharm; 2011 Jun; 411(1-2):78-85. PubMed ID: 21453763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an ex vivo method for evaluation of precorneal residence of topical ophthalmic formulations.
    Liu Q; Wang Y
    AAPS PharmSciTech; 2009; 10(3):796-805. PubMed ID: 19521781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses.
    Gause S; Hsu KH; Shafor C; Dixon P; Powell KC; Chauhan A
    Adv Colloid Interface Sci; 2016 Jul; 233():139-154. PubMed ID: 26318359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Permeability of the cornea to topically applied drugs.
    Benson H
    Arch Ophthalmol; 1974 Apr; 91(4):313-27. PubMed ID: 4621283
    [No Abstract]   [Full Text] [Related]  

  • 7. The influence of the osmolality on the precorneal retention of ophthalmic solutions.
    Ludwig A; Van Ooteghem M
    J Pharm Belg; 1987; 42(4):259-66. PubMed ID: 3694417
    [No Abstract]   [Full Text] [Related]  

  • 8. Prolonged-action drops.
    Maurice DM
    Int Ophthalmol Clin; 1993; 33(4):81-91. PubMed ID: 8258500
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of various concentrations of terpene-4-ol enhancer and carbopol-934 mucoadhesive upon the in vitro ocular transport and the in vivo intraocular pressure lowering effects of dorzolamide ophthalmic formulations using albino rabbits.
    Afouna MI; Khedr A; Abdel-Naim AB; Al-Marzoqi A
    J Pharm Sci; 2010 Jan; 99(1):119-27. PubMed ID: 19530071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and evaluation of a timolol maleate drug-resin ophthalmic suspension as a sustained-release formulation in vitro and in vivo.
    Qin F; Zeng L; Zhu Y; Cao J; Wang X; Liu W
    Drug Dev Ind Pharm; 2016; 42(4):535-45. PubMed ID: 26368660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and evaluation of a novel in situ gel of sparfloxacin for sustained ocular drug delivery: in vitro and ex vivo characterization.
    Khan N; Aqil M; Imam SS; Ali A
    Pharm Dev Technol; 2015; 20(6):662-9. PubMed ID: 24754411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient analysis of ocular drug delivery: zero-volume effect.
    Keister JC; Heidmann PS; Missel PJ
    J Pharm Sci; 1997 Sep; 86(9):1040-5. PubMed ID: 9294819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thermosensitive in situ nanogel as ophthalmic delivery system of curcumin: development, characterization, in vitro permeation and in vivo pharmacokinetic studies.
    Liu R; Sun L; Fang S; Wang S; Chen J; Xiao X; Liu C
    Pharm Dev Technol; 2016 Aug; 21(5):576-82. PubMed ID: 26024239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and evaluation of nanoparticles loaded ophthalmic in situ gel.
    Kesarla R; Tank T; Vora PA; Shah T; Parmar S; Omri A
    Drug Deliv; 2016 Sep; 23(7):2363-2370. PubMed ID: 25579467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained release ophthalmic formulations of pilocarpine.
    Deshpande SG; Shirolkar S
    J Pharm Pharmacol; 1989 Mar; 41(3):197-200. PubMed ID: 2568450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temperature sensitive contact lenses for triggered ophthalmic drug delivery.
    Jung HJ; Chauhan A
    Biomaterials; 2012 Mar; 33(7):2289-300. PubMed ID: 22182750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corneal penetration and ocular bioavailability of drugs.
    Burstein NL; Anderson JA
    J Ocul Pharmacol; 1985; 1(3):309-26. PubMed ID: 3916851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biological availability of ophthalmic drugs. 1. Increasing drug permeability in the cornea].
    Masteiková R; Chalupová Z; Savickiene N
    Ceska Slov Farm; 2004 Mar; 53(2):73-9. PubMed ID: 15095575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dispersion of microemulsion drops in HEMA hydrogel: a potential ophthalmic drug delivery vehicle.
    Gulsen D; Chauhan A
    Int J Pharm; 2005 Mar; 292(1-2):95-117. PubMed ID: 15725557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precorneal residence time of artificial tears measured in dry eye subjects.
    Paugh JR; Nguyen AL; Ketelson HA; Christensen MT; Meadows DL
    Optom Vis Sci; 2008 Aug; 85(8):725-31. PubMed ID: 18677236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.